株式会社グローバルインフォメーション
TEL: 044-952-0102
市場調査レポート

世界の非オピオイド鎮痛パッチ市場:パッチタイプ、流通経路、地域別

Non-opioid Pain Patch Market - Growth, Trends, and Forecast (2020 - 2025)

発行 Mordor Intelligence LLP 商品コード 704955
出版日 ページ情報 英文 120 Pages
納期: 2-3営業日
価格
本日の銀行送金レート: 1USD=111.31円で換算しております。
Back to Top
世界の非オピオイド鎮痛パッチ市場:パッチタイプ、流通経路、地域別 Non-opioid Pain Patch Market - Growth, Trends, and Forecast (2020 - 2025)
出版日: 2020年02月01日 ページ情報: 英文 120 Pages
担当者のコメント
下記の日本語概要は、最新版レポートの内容と異なる場合があります。詳細はお問合せください。
概要

世界の非オピオイド鎮痛パッチ市場は、2018年から2023年の予測期間を通じて3.5%のCAGRで推移することが予測されています。

当レポートでは、世界の非オピオイド鎮痛パッチ市場を調査し、市場の概要、パッチタイプ・流通経路・地域別の市場規模の推移と予測、市場動向、市場の成長要因および阻害要因の分析、市場機会、競合情勢、主要企業のプロファイルなど、包括的な情報を提供しています。

目次

第1章 イントロダクション

  • 市場の定義

第2章 調査方法

第3章 エグゼクティブサマリー

第4章 主な影響要因

第5章 市場の概要

  • 現在の市場シナリオ
  • ファイブフォース分析
    • 買い手の交渉力
    • 供給企業の交渉力
    • 新規参入業者の脅威
    • 代替品の脅威
    • 競争企業間の敵対関係

第6章 市場のダイナミクス

  • 成長要因
    • 疼痛関連疾患の疾病負荷の上昇
    • 疼痛管理治療の研究開発の増加
    • オピオイド薬の副作用に対する認識向上
  • 阻害要因
    • 代替療法の存在
    • パッチの接着性の問題と認知度の低さ
  • 市場機会
  • 主な課題

第7章 市場セグメンテーション

  • パッチタイプ別
    • カプサイシンパッチ
    • ジクロフェナックパッチ
    • ケトプロフェンパッチ
    • リドカインパッチ
    • サリチル酸メチルパッチ
    • その他
  • 流通経路別
    • 病院薬局
    • 小売薬局
    • その他
  • 地域別
    • 北米
    • 欧州
    • アジア太平洋地域
    • 中東・アフリカ
    • 南米

第8章 競合情勢

  • M&A分析
  • 合意、コラボレーション、パートナーシップ
  • 新製品の発売

第9章 主要企業

  • Acorda Therapeutics, Inc.
  • Allergan
  • Endo Pharmaceuticals PLC
  • GlaxoSmithKline PLC
  • 久光製薬
  • IBSA Institut Biochimque SA
  • Mylan NV
  • Pfizer, Inc
  • TEH SENG Pharmaceutical Mfg. Co., Ltd.
  • 帝國製薬

第10章 市場の将来展望

目次
Product Code: 64062

Pain has a deeper impact on the socio-economic system than the combination of cardiovascular diseases, cancer, and diabetes together. The International Agency for Research on Cancer (IARC) predicts that, by 2030, the global burden is expected to increase to 21.7 million new cancer cases and 13 million cancer deaths. Similarly, cardiovascular disease (CVD) is one of the main causes of death among the adult population, globally. Chronic pain initiates in numerous ways, for instance, from trauma which could include an accident or back strain due to heavy lifting among other ways, an underlying disease like pancreatitis, spine disease, arthritis, and autoimmune diseases, or it can occur with fibromyalgia or persistent migraines. As per, CDC around 43% of the population suffer from pain on some days and around 20% of the population suffer from pain every day or on most days. There are numerous risk factors for chronic pain. Non-opioid patches are more preferable because it does not involve the risk of addiction as with opioid drug patches like fentanyl patches and also the drugs is released over a long period of time, therefore, helping in managing the pain for a longer duration and considered as a valuable driver for this market.

However, availability of alternative treatments and low adoption rate of non-opioid pain patch due to unawareness is expected to impede the growth of non-opioid pain patch market.

Key Market Trends

Lidocaine Patches Segment is Expected to Show Better Growth in the Forecast Years

Based on type, the market is segmented into lidocaine patches, diclofenac patches, capsaicin patches, ketoprofen patches, and others. Lidocaine patches are considered as the most commonly available patch for the treatment of chronic and acute pain. According to the American Academy of Pain Medicine (AAPM), chronic pain affects approximately 1.5 billion people worldwide with prevalence increasing with age. The proportion of the world's population over 60 years will nearly double from 12% to 22%, between 2015 and 2050, as per WHO estimates. Lidocaine patches are recommended as first-line therapy for the treatment of neuropathic pain in older patients, which is expected to boost the market growth. Furthermore, the increasing burden of diseases, along with safety profile and efficacy associated with lidocaine patches are expected to drive the market growth during the forecast period.

North America is Expected to Dominate the Non-opioid Pain Patch Market

North America is expected to retain its dominance in this market. chronic pain is one of the primary factors responsible for the growth of the market. According to the National Institute of Health (NIH), in 2016, around 20% of US adults were suffering from chronic pain and 8% had high impact, which at least limits one major life activity in the patient. In addition, the countries in North America are increasingly facing scrutiny on the opioid crises issue, from the government authorities, which in turn are expected to benefit the rise of non-opioid alternatives. Thus, rising disease burden is further pushing the need for effective and quick treatment options which is expected to propel the growth of the market, over the forecast period.

Competitive Landscape

The global players in the non-opioid pain patch market are - Clarion Brands Inc., Endo Pharmaceuticals, Hisamitsu Pharmaceutical, Sanofi, Sorrento Therapeutics (SCILEX Pharmaceuticals), TEH SENG Pharmaceutical, Teikoku Seiyaku, Teva Pharmaceuticals, and Veridian Healthcare.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • Report customization as per the client's requirements
  • 3 months of analyst support

Table of Contents

1 INTRODUCTION

  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increasing Burden of Pain-Related Disorders
    • 4.2.2 Rising R&D in Pain Management Treatments
    • 4.2.3 Benefits Associated with Non-opioid Pain Patches over Conventional Medications
  • 4.3 Market Restraints
    • 4.3.1 Availability of Alternative Treatments
    • 4.3.2 Low Adoption Rate of Non-opioid Pain Patch due to Unawareness
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Patch Type
    • 5.1.1 Lidocaine Patches
    • 5.1.2 Diclofenac Patches
    • 5.1.3 Capsaicin Patches
    • 5.1.4 Ketoprofen Patches
    • 5.1.5 Others
  • 5.2 By Distribution Channel
    • 5.2.1 Hospital Pharmacies
    • 5.2.2 Retail Pharmacies
    • 5.2.3 Others
  • 5.3 Geography
    • 5.3.1 North America
      • 5.3.1.1 United States
      • 5.3.1.2 Canada
      • 5.3.1.3 Mexico
    • 5.3.2 Europe
      • 5.3.2.1 Germany
      • 5.3.2.2 United Kingdom
      • 5.3.2.3 France
      • 5.3.2.4 Italy
      • 5.3.2.5 Spain
      • 5.3.2.6 Rest of Europe
    • 5.3.3 Asia-Pacific
      • 5.3.3.1 China
      • 5.3.3.2 Japan
      • 5.3.3.3 India
      • 5.3.3.4 Australia
      • 5.3.3.5 South Korea
      • 5.3.3.6 Rest of Asia-Pacific
    • 5.3.4 Middle-East and Africa
      • 5.3.4.1 GCC
      • 5.3.4.2 South Africa
      • 5.3.4.3 Rest of Middle-East and Africa
    • 5.3.5 South America
      • 5.3.5.1 Brazil
      • 5.3.5.2 Argentina
      • 5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Clarion Brands Inc.
    • 6.1.2 Endo Pharmaceuticals Inc.
    • 6.1.3 Hisamitsu Pharmaceutical Co. Inc.
    • 6.1.4 Sanofi S.A.
    • 6.1.5 Sorrento Therapeutics (SCILEX Pharmaceuticals)
    • 6.1.6 TEH SENG Pharmaceutical Mfg Co
    • 6.1.7 Teikoku Seiyaku Co. Ltd.
    • 6.1.8 Teva Pharmaceuticals Industries Ltd.
    • 6.1.9 Veridian Healthcare

7 MARKET OPPORTUNITIES AND FUTURE TRENDS

Back to Top